PolyPEPI1018 an investigational off-the-shelf vaccine for colorectal cancer induced promising immune responses and clinical signs of efficacy when given in combination with standard maintenance therapy in metastatic colorectal cancer patients.
PolyPEPI1018 is an off-the-shelf cancer vaccine consisting of six synthetic protein fragments that induce immune responses against seven proteins commonly found in colorectal cancer cells.
Producing long-lasting responses against colorectal tumors, while sparing healthy cells, because the immune system becomes primed for several cancer proteins, the vaccine is able to target multiple cancer cells.
PolyPEPI1018 is indicated for treating colorectal cancer
June 3, 2019: The findings from the company’s first-in-human trial were presented June 3 at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, in a poster titled “A phase I study of PolyPEPI1018 vaccine plus maintenance therapy in patients with metastatic colorectal cancer with a predictive biomarker (OBERTO).”
Clinical Trials NCT03391232: PolyPEPI1018 Vaccine and CDx for the Treatment of Metastatic Colorectal Cancer (OBERTO)
- This Phase I/II clinical trial investigates the safety, tolerability, immunogenicity and preliminary efficacy of multiple doses of PolyPEPI1018 CRC vaccine as an add-on treatment to the standard-of-care maintenance therapy in patients with metastatic colorectal cancer.
- Clinical responses will be evaluated by indiction of T cell responses, T lymphocyte infiltration in accessible biopsy sites, and by objective tumor responses.
- This study will also explore the accuracy of the predicted T cell responses in each patient using the candidate companion diagnostic test and the correlations between clinical responses and predicted T cell responses.